3 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMORecruiting
Are there differences is efficacy, side effects, tolerance en costs in patients with early RA in treatment with COBRA-light compared with COBRA according to BeSt?
Approved WMORecruiting
Our study at 'de Waag' (an outpatient forensic mental health institution) would provide a first impression of the added value of adding VR to the treatment of aggression regulation problems.Results from the study are also useful for…